Orion Oyj (OTCMKTS:ORINY) Sees Large Increase in Short Interest

Orion Oyj (OTCMKTS:ORINY) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 600 shares, an increase of 20.0% from the February 13th total of 500 shares. Based on an average daily volume of 700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.0% of the shares of the company are sold short.

Orion Oyj Stock Performance

Shares of OTCMKTS:ORINY opened at $30.57 on Thursday. The business’s fifty day moving average price is $27.11 and its two-hundred day moving average price is $25.54. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. Orion Oyj has a fifty-two week low of $17.50 and a fifty-two week high of $30.57. The stock has a market capitalization of $8.63 billion, a price-to-earnings ratio of 24.26 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last posted its earnings results on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. The business had revenue of $463.41 million during the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. As a group, analysts predict that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The company also recently announced a dividend, which will be paid on Tuesday, April 29th. Investors of record on Monday, April 7th will be given a $0.4478 dividend. This is an increase from Orion Oyj’s previous dividend of $0.24. The ex-dividend date of this dividend is Monday, April 7th. Orion Oyj’s payout ratio is presently 26.40%.

Analyst Ratings Changes

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.